- Home
- SGA vs NRXP Comparison
SGA vs NRXP Comparison
Compare SGA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | NRXP |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 62.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGA | NRXP |
|---|---|---|
| Price | $11.81 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 7.3K | ★ 533.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.53 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $10.68 | $1.58 |
| 52 Week High | $14.27 | $3.84 |
Technical Indicators
Market Signals| Indicator | SGA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 47.88 |
| Support Level | $11.75 | $1.65 |
| Resistance Level | $11.99 | $2.79 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 42.77 | 76.27 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.